Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens
Vaccines · 27.06.2024 · 12 (7) · 717
DOI: 10.3390/vaccines12070717 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 27.06.2024. Verfasst von Qing Hao und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, Department of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Key R&D Program of China, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Neoantigens, presented as peptides on the surfaces of cancer cells, have recently been proposed as optimal targets for immunotherapy in clinical practice. The promising outcomes of neoantigen-based cancer vaccines have inspired enthusiasm for their broader clinical applications. However, the individualized tumor-specific antigens (TSA) entail considerable costs and time due to the variable immunogenicity and response rates of these neoantigens-based vaccines, influenced by factors such as neoantigen response, vaccine types, and combination therapy. Given the crucial role of neoantigen efficacy, a number of bioinformatics algorithms and pipelines have been developed to improve the accuracy rate of prediction through considering a series of factors involving in HLA-peptide-TCR complex formation, including peptide presentation, HLA-peptide affinity, and TCR recognition. On the other hand, shared neoantigens, originating from driver mutations at hot mutation spots (e.g., KRASG12D), offer a promising and ideal target for the development of therapeutic cancer vaccines. A series of clinical practices have established the efficacy of these vaccines in patients with distinct HLA haplotypes. Moreover, increasing evidence demonstrated that a combination of tumor associated antigens (TAAs) and neoantigens can also improve the prognosis, thus expand the repertoire of shared neoantigens for cancer vaccines. In this review, we provide an overview of the complex process involved in identifying personalized neoantigens, their clinical applications, advances in vaccine technology, and explore the therapeutic potential of shared neoantigen strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy and Cancer Center, Department of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
- Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
- Gastric Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
- Institute of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
- Research Center of Clinical Laboratory Medicine, Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Förderung
- National Key R&D Program of China
- National Key R&D Program of China
- Natural Science Foundation of Sichuan Province
- 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
Zitieren
APA
Hao, Q., Long, Y., Yang, Y., Deng, Y., Ding, Z., Yang, L., Shu, Y., & Xu, H. (2024). Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens. Vaccines, 12(7), 717. https://doi.org/10.3390/vaccines12070717
Vancouver
Hao Q, Long Y, Yang Y, Deng Y, Ding Z, Yang L, et al. Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens. Vaccines. 2024;12(7):717. doi:10.3390/vaccines12070717
BibTeX
@article{Hao2024,
author = {Hao, Qing and Long, Yuhang and Yang, Yi and Deng, Yiqi and Ding, Zhenyu and Yang, Li and Shu, Yang and Xu, Heng},
title = {Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {7},
pages = {717},
doi = {10.3390/vaccines12070717}
}
EUVIMED